Skip to content

Exploratory Study on Vagus Nerve Stimulation (VNS) for the Treatment of Autism Spectrum Disorder (ASD)

Exploratory Study on Vagus Nerve Stimulation (VNS) for the Treatment of Autism Spectrum Disorder (ASD)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500115313
Enrollment
Unknown
Registered
2025-12-24
Start date
2024-12-07
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism Spectrum Disorder

Interventions

VNS:None

Sponsors

Beijing Children's Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. Children aged 3–18 years who meet the diagnostic criteria for Autism Spectrum Disorder (ASD) as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V); 2. Subjects or their guardians are able to fully understand the therapy and provide signed informed consent; 3. Subjects or their family members are capable of cooperating with relevant scale assessment tests; 4. Subjects who have received formal and stable doses of psychiatric medication for at least 6 months prior to enrollment without efficacy and agree not to initiate new or modify existing medication or behavioral interventions.

Exclusion criteria

Exclusion criteria: 1) Implantation of active implantable medical devices (such as pacemakers, implantable hearing aids, etc.) or metal devices, such as stents, bone plates, or bone screws. 2) Comorbid physical or mental illnesses that may impair the ability to tolerate vagus nerve stimulation or comply with study requirements (e.g., insulin-dependent diabetes mellitus, bipolar disorder, etc.). 3) Vagus nerve lesions, injuries, or structural abnormalities (such as lymphadenopathy, tumors, or previous surgeries) or pain. 4) Current or past history of neurological diseases or trauma, including uncontrolled epilepsy and head injuries. 5) Current or recent (within 12 months) participation in clinical trials of drugs or medical devices. 6) Use of drugs affecting the autonomic nervous system (ß-blockers, ß-stimulants, etc.) within 4 weeks. 7) Use of cannabis (including medical cannabis) for any indication. 8) Specific allergic constitution that cannot tolerate foreign body implantation. 9) Poor general physical condition that cannot tolerate surgery, etc.

Design outcomes

Primary

MeasureTime frame
Autism behavior checklist,ABC;

Secondary

MeasureTime frame
Child autism rating scale,CARS;Autism diagnostic observation schedule;The Wechsler Intelligence Scale for Children, WISC;

Countries

China

Contacts

Public ContactTInghong Liu

Beijing Children's Hospital, Capital Medical University

liutinghong1@163.com+86 188 0127 8650

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026